AIM ImmunoTech Sets July 2026 Enrollment and August Dosing Milestones in Phase 2 Trial
AIM ImmunoTech’s Phase 2 DURIPANC trial has enrolled 18 metastatic pancreatic cancer patients, planning to complete enrollment by July 2026 and Ampligen dosing by August 2026. The study’s primary endpoint of Clinical Benefit Rate at 24 weeks is set for December 2026, with PFS and OS evaluated by June 2027.
1. Planned DURIPANC Milestones
The DURIPANC Phase 2 study will complete subject enrollment by July 2026 and finish full Ampligen dosing by August 2026. The primary endpoint, Clinical Benefit Rate at 24 weeks, is slated for evaluation in December 2026, with secondary endpoints—Progression-Free Survival, Overall Survival and immunogenic efficacy—assessed by June 2027.
2. Trial Design and Collaboration
DURIPANC is an investigator-initiated, open-label, single-center study conducted in partnership with AstraZeneca and Erasmus Medical Center in the Netherlands. Eighteen patients with stable disease post-FOLFIRINOX have enrolled to date, supporting the exploratory investigation of Ampligen combined with durvalumab.
3. Safety Profile and Interim Reporting
Interim reports show no significant toxicity and consistently high quality-of-life scores among subjects. AIM ImmunoTech plans to release mid-year and year-end progress updates, with detailed data expected later this year to inform potential Phase 3 advancement.